Holen Sie sich die Stockscreener-App
297.88
1.43%
4.21
Handel nachbörslich:
297.88
Schlusskurs vom Vortag:
$293.67
Offen:
$292.81
24-Stunden-Volumen:
199.90K
Relative Volume:
0.60
Marktkapitalisierung:
$6.55B
Einnahmen:
$2.58B
Nettoeinkommen (Verlust:
$-778.69M
KGV:
-10.90
EPS:
-27.33
Netto-Cashflow:
$223.75M
1W Leistung:
-1.96%
1M Leistung:
+17.93%
6M Leistung:
+12.14%
1J Leistung:
-10.74%
1-Tages-Spanne:
$292.81
$300.85
1-Wochen-Bereich:
$288.98
$301.52
52-Wochen-Spanne:
$211.43
$387.99
Bio Rad Laboratories Inc Stock (BIO) Company Profile
Firmenname
Bio Rad Laboratories Inc
Sektor
Branche
Telefon
(510) 724-7000
Adresse
1000 ALFRED NOBEL DRIVE, HERCULES
Vergleichen Sie BIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIO
Bio Rad Laboratories Inc
|
297.88 | 7.95B | 2.58B | -778.69M | 223.75M | -27.33 |
|
ABT
Abbott Laboratories
|
132.66 | 228.64B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
105.50 | 156.70B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
391.41 | 148.97B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.81 | 117.96B | 34.20B | 4.69B | 5.30B | 3.63 |
|
EW
Edwards Lifesciences Corp
|
81.34 | 47.69B | 5.69B | 1.41B | 577.90M | 6.95 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-04-03 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-12-07 | Eingeleitet | UBS | Buy |
| 2023-06-16 | Eingeleitet | Wells Fargo | Overweight |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-01-28 | Bestätigt | Citigroup | Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2018-10-17 | Eingeleitet | Goldman | Buy |
| 2018-09-20 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2018-02-16 | Herabstufung | CL King | Buy → Neutral |
| 2017-07-13 | Eingeleitet | Wells Fargo | Outperform |
| 2017-06-28 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Hold |
| 2016-10-13 | Eingeleitet | CL King | Buy |
| 2015-05-06 | Bestätigt | Jefferies | Buy |
| 2009-12-18 | Eingeleitet | Maxim Group | Buy |
| 2009-11-06 | Eingeleitet | Jefferies & Co | Buy |
| 2009-07-17 | Eingeleitet | Soleil | Buy |
| 2007-09-26 | Eingeleitet | Banc of America Sec | Buy |
| 2007-02-23 | Herabstufung | Robert W. Baird | Outperform → Neutral |
Alle ansehen
Bio Rad Laboratories Inc Aktie (BIO) Neueste Nachrichten
How to forecast Bio Rad Laboratories Inc. trends using time seriesJuly 2025 Volume & Fast Exit and Entry Strategy Plans - Newser
What earnings revisions data tells us about Bio Rad Laboratories Inc.IPO Watch & Trade Opportunity Analysis - Newser
How institutional ownership impacts Bio Rad Laboratories Inc. stockTrade Risk Assessment & Weekly Stock Performance Updates - Newser
Will Bio Rad Laboratories Inc. price bounce be sustainable2025 Stock Rankings & Weekly Setup with ROI Potential - Newser
Is this a good reentry point in Bio Rad Laboratories Inc.Weekly Investment Recap & Free AI Powered Buy and Sell Recommendations - Newser
Real time breakdown of Bio Rad Laboratories Inc. stock performanceTrade Exit Summary & Safe Entry Zone Identification - Newser
Can swing trading help recover from Bio Rad Laboratories Inc. lossesJuly 2025 Recap & Precise Swing Trade Alerts - Newser
What’s the recovery path for long term holders of Bio Rad Laboratories Inc.July 2025 Breakouts & AI Powered Market Trend Analysis - Newser
What data driven models say about Bio Rad Laboratories Inc.’s futureTrade Entry Report & AI Forecasted Entry/Exit Points - Newser
Heatmap analysis for Bio Rad Laboratories Inc. and competitorsTrade Volume Report & AI Driven Stock Reports - Newser
What does recent volatility data suggest for Bio Rad Laboratories Inc.Portfolio Return Report & Real-Time Buy Zone Alerts - Newser
Smart tools for monitoring Bio Rad Laboratories Inc.’s price actionEarnings Trend Report & Verified Short-Term Trading Plans - Newser
How high can Bio Rad Laboratories Inc. stock price go in 2025July 2025 Reactions & Growth Focused Stock Reports - Newser
Risk adjusted return profile for Bio Rad Laboratories Inc. analyzedJuly 2025 PostEarnings & Real-Time Chart Breakout Alerts - Newser
Published on: 2025-08-29 11:31:02 - Newser
Published on: 2025-08-29 16:45:51 - beatles.ru
Analyzing drawdowns of Bio Rad Laboratories Inc. with statistical toolsBreakout Watch & Free Risk Controlled Daily Trade Plans - Newser
Sentiment analysis tools applied to Bio Rad Laboratories Inc.Weekly Market Summary & Momentum Based Trading Ideas - Newser
Applying big data sentiment scoring on Bio Rad Laboratories Inc.Market Sentiment Summary & Accurate Buy Signal Alerts - Newser
Lyme Disease Pipeline 2025: In-depth Clinical Trials Analysis and Emerging Therapies Report by DelveInsight | Abbott, Bio-Rad Laboratories, Inc., Covance Inc.F. Hoffmann-La Roche AG, T2 Biosystems - The Globe and Mail
Real time social sentiment graph for Bio Rad Laboratories Inc.Product Launch & Fast Exit and Entry Strategy Plans - Newser
Tools to assess Bio Rad Laboratories Inc.’s risk profile2025 Retail Activity & Safe Investment Capital Preservation Plans - Newser
Finanzdaten der Bio Rad Laboratories Inc-Aktie (BIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Bio Rad Laboratories Inc-Aktie (BIO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ENGELHARDT EVA ANETTE | EVP, President, CDG |
Jul 25 '25 |
Option Exercise |
0.00 |
245 |
0 |
245 |
| Lakkaraju Roop Kalyan | EVP, Chief Financial Officer |
Apr 24 '25 |
Option Exercise |
0.00 |
1,077 |
0 |
1,231 |
| ENLOE COURTNEY C | EVP, General Counsel & Sec |
Apr 24 '25 |
Option Exercise |
0.00 |
186 |
0 |
196 |
| PINKSTON ARNOLD A | Director |
Apr 22 '25 |
Option Exercise |
0.00 |
308 |
0 |
308 |
| PEI MELINDA LITHERLAND | Director |
Apr 22 '25 |
Option Exercise |
0.00 |
308 |
0 |
308 |
| HINCKLEY GREGORY K | Director |
Apr 22 '25 |
Option Exercise |
0.00 |
308 |
0 |
308 |
| EDWARDS JEFFREY L | Director |
Apr 22 '25 |
Option Exercise |
0.00 |
308 |
0 |
308 |
| Crowley Michael | EVP, GBL Commercial Operations |
Mar 14 '25 |
Option Exercise |
159.32 |
3,000 |
477,960 |
11,171 |
| Crowley Michael | EVP, GBL Commercial Operations |
Mar 14 '25 |
Sale |
247.06 |
3,000 |
741,184 |
8,171 |
0.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):